Qyuns Therapeutics Co., Ltd.

SEHK:2509 Stock Report

Market Cap: HK$2.1b

Qyuns Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure2.5yrs
Board average tenure3.4yrs

Recent management updates

Recent updates

Is Qyuns Therapeutics (HKG:2509) Weighed On By Its Debt Load?

Sep 19
Is Qyuns Therapeutics (HKG:2509) Weighed On By Its Debt Load?

CEO

Qyuns Therapeutics has no CEO, or we have no data on them.

Leadership Team

NamePositionTenureCompensationOwnership
Yiliang Wu
Executive Director & Executive Deputy GM of Cellularforce1.9yrsCN¥6.26mno data
Weidong Lin
Deputy GM & Executive Director3.4yrsCN¥8.73mno data
Min Fang
Deputy General Manager7.2yrsno datano data
Yanbao Hu
Board Secretary & Joint Company Secretary2.5yrsno datano data
King Yin Tang
Joint Company Secretary1.9yrsno datano data

2.5yrs

Average Tenure

41yo

Average Age

Experienced Management: 2509's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yiliang Wu
Executive Director & Executive Deputy GM of Cellularforce5.8yrsCN¥6.26mno data
Weidong Lin
Deputy GM & Executive Director2.9yrsCN¥8.73mno data
Che Wai Fung
Independent Non-Executive Director1.1yrsno datano data
Jiwan Qiu
GM & Chairman of the Board9.7yrsCN¥58.11mno data
Xi Yu
Non-Executive Director4.5yrsno datano data
Zhiqiang Wu
Non-Executive Director3.4yrsno datano data
Zhongmei Zou
Independent Non-Executive Director1.1yrsno datano data
Jianqun Ling
Independent Non-Executive Director1.1yrsno datano data
Xiang Ye
Independent President of the Supervisor3.4yrsno datano data
Chao Ding
Independent Supervisor2.4yrsno datano data
Yujiao Wang
Employee Representative Supervisor3.4yrsno datano data

3.4yrs

Average Tenure

50yo

Average Age

Experienced Board: 2509's board of directors are considered experienced (3.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/03 13:12
End of Day Share Price 2025/01/28 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Qyuns Therapeutics Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution